C-UPQDVero Biosciences
proteomics, machine learning, organ aging
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-UPQD
C-UPQDC-UPQDproteomics, machine learning, organ aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Vero Biosciences proteomics, machine learning, organ aging
Vero Bioscience measures organ-level biological age using thousands of blood proteins with organ-specific signatures. Its Proteomic OrganAge analysis reports percentiles relative to age-matched peers and is intended to identify early molecular signs of age-related change. The company says its Vero Compass platform is under development for integrating biological, clinical, and wearable data to guide interventions and monitor organ response over time.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Vero Biosciences — Far from goals · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic